Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Life Science & Biotech
Articles
Indiana Seed Fund makes 11th investment
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
Lilly Alzheimer’s imaging agent to get priority FDA review
Eli Lilly and Co. said the Food and Drug Administration will perform a faster review of florbetapir, an imaging agent that may help diagnose Alzheimer's disease.
Zimmer looks to China to reignite growth
Zimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe are trumping all other factors and keeping the company’s growth bottled up for now.
Lilly Endowment gives $35M to start pharmacy school
Manchester College will use money to launch the state’s third program offering doctorates in pharmacy.
Biomet owners look to arrange $11B marriage
Warsaw-based Biomet Inc. could get a whole lot bigger if rumors prove true that its owners have made a bid for U.K.-based rival Smith & Nephew plc.
State adds record number of life sciences jobs
Twenty companies committed this year to add more than 4,000 jobs.
Dow AgroSciences moves into new research facility
The division of Dow Chemical has a 15-year lease with Indianapolis-based developer Browning Investments on the two-story building near West 96th Street.
Medical device maker expanding in Fort Wayne
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its manufacturing operations.
Lilly scores series of small victories
The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Drugmaker restarts race to boost ‘good’ cholesterol
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
Acquisition big step for Lilly Diagnostics
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
Lilly makes $300M deal for Philadelphia drug company
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
Indiana life sciences upstarts tap health reform booty
The federal legislation is roundly criticized at a BioCrossroads meeting, but some firms have found a silver lining.
Seeking growth, Lilly dumps Singapore for China
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Lilly to open diabetes research center in China
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Indiana’s life sciences industry sees trouble ahead
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Indiana life sciences sector copes with shrinking VC pool
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.